BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
293.27
-11.35 (-3.73%)
At close: May 15, 2026, 4:00 PM EDT
298.00
+4.73 (1.61%)
After-hours: May 15, 2026, 7:46 PM EDT
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of $1.51B in the quarter ending March 31, 2026, with 35.46% growth. This brings the company's revenue in the last twelve months to $5.74B, up 37.44% year-over-year. In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth.
Revenue (ttm)
$5.74B
Revenue Growth
+37.44%
P/S Ratio
5.72
Revenue / Employee
$475,411
Employees
12,000
Market Cap
32.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| Incyte | 5.36B |
| argenx SE | 4.74B |
| Alnylam Pharmaceuticals | 4.29B |
| Genmab | 3.90B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
ONC News
- 2 days ago - BeOne Medicines price target raised to $367 from $364 at Leerink - TheFly
- 4 days ago - BeOne Medicines (ONC) Receives FDA Fast-Tracked Approval for Beqalzi - GuruFocus
- 4 days ago - BeOne Medicines’ Beqalzi granted accelerated approval by FDA - TheFly
- 4 days ago - US FDA approves BeOne's drug for a type of blood cancer - Reuters
- 4 days ago - BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - Business Wire
- 4 days ago - BeOne Medicines’ BEQALZI (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma - Wallstreet:Online
- 10 days ago - BeOne Medicines price target raised to $395 from $389 at Morgan Stanley - TheFly
- 10 days ago - BeOne Medicines price target raised to $409 from $405 at Barclays - TheFly